上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：浙江泰林生物技术股份有限公司 单位：万元 | | 浙江泰林科 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 学技术有限 | 全资子公司 | 其他应收款 | 4540 | 900 | | 6090 | -650 | 拆借款 非经营性往来 | | | 公司 | | | | | | | | | | | 北京沃锶达 | | | | | | | | | | | 细胞技术有 | 控股子公司 | 其他应收款 | | | | | | 拆借款 非经营性往来 | | | 限公司 | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | 总计 | - | - - | | 4540 | 9739.80 | 0 | 9582.80 | 4697 | - | | 法定代表人：叶大林 | | | | 主管会计工作负责人：叶星月 | | | | | 会计机构负责人：周文琴 | | 非经营性 ...

| 证券代码：300813 | 证券简称：泰林生物 | 公告编号：2023-051 | | --- | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | | 浙江泰林生物技术股份有限公司 关于取得专利证书及商标注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰 林生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司 （以下简称"泰林医学工程"）于近期共取得了 15 项专利证书（其中发明专利 5 项）以及 2 项商标注册证书，具体情况如下： 序号 专利名称 专利类型 申请号 授权公告日 专利权人 1 一种高效低阻超疏水纳米纤维复 合膜的制备方法 发明专利 2022103352933 2023/8/1 泰林生命科学 2 一种二氧化碳培养系统 发明专利 2019109957567 2023/6/2 泰林医学工程 3 一种过氧化氢瞬时灭菌装置及灭 菌方法 发明专利 2019114060655 2023/6/2 泰林医学工程 4 一种集菌仪结构 ...

Financial Performance - The company's revenue for Q1 2023 was ¥78,946,553.19, representing a 10.36% increase compared to ¥71,534,758.17 in the same period last year[5] - Net profit attributable to shareholders was ¥17,575,025.59, up 26.21% from ¥13,925,179.08 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 78,946,553.19, an increase of 10.8% compared to CNY 71,534,758.17 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 17,575,025.59, representing a 26.5% increase from CNY 13,925,179.08 in Q1 2022[20] - Basic earnings per share decreased by 22.22% to ¥0.21 from ¥0.27 in the same period last year[5] - Basic earnings per share for Q1 2023 were CNY 0.21, down from CNY 0.27 in Q1 2022[21] - Other income for Q1 2023 was CNY 4,217,745.67, significantly higher than CNY 105,289.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥17,807,115.09, a significant decline of 611.56% compared to -¥2,502,547.74 in the previous year[5] - The net cash flow from operating activities for Q1 2023 was -CNY 17,807,115.09, compared to -CNY 2,502,547.74 in Q1 2022, indicating a decline in cash flow[22] - The net cash flow from investing activities was -61,746,781.25 CNY, compared to -55,585,743.44 CNY in the previous period, indicating an increase in cash outflow[23] - Cash inflow from financing activities totaled 3,000,000.00 CNY, significantly lower than 205,800,000.00 CNY in the previous period[23] - The net cash flow from financing activities was -9,908.47 CNY, a sharp decline from 204,469,339.64 CNY in the previous period[23] - The total cash and cash equivalents at the end of the period were 202,059,043.61 CNY, down from 319,191,845.37 CNY in the previous period[23] - The net increase in cash and cash equivalents was -79,563,804.81 CNY, contrasting with an increase of 146,371,343.00 CNY in the previous period[23] - The company reported a total cash outflow from investing activities of 81,768,109.55 CNY, compared to 75,645,743.44 CNY in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥922,917,372.63, a slight increase of 0.03% from ¥922,660,005.83 at the end of the previous year[5] - The total assets of Zhejiang Tailin Biotechnology Co., Ltd. as of March 31, 2023, amounted to CNY 922,917,372.63, showing a slight increase from CNY 922,660,005.83 at the beginning of the year[16] - The company's cash and cash equivalents decreased to CNY 548,796,995.73 from CNY 577,153,986.25, reflecting a decline of approximately 4.5%[16] - Accounts receivable increased to CNY 54,583,843.48 from CNY 42,578,297.85, representing a growth of about 28.3%[16] - Inventory decreased to CNY 107,337,687.08 from CNY 111,201,218.36, indicating a reduction of approximately 3.4%[16] - Current liabilities decreased to CNY 105,402,583.19 from CNY 129,326,260.25, a decline of about 18.5%[17] - The total liabilities decreased to CNY 254,205,720.40 from CNY 275,205,185.78, reflecting a decrease of approximately 7.6%[17] - The company's total equity attributable to shareholders increased to CNY 668,711,652.23 from CNY 647,454,820.05 year-over-year[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,781[10] - The largest shareholder, Ye Daling, holds 53.48% of the shares, totaling 44,480,000 shares[10] - The company has a significant shareholder, Ye Daling, holding 11,120,000 shares, which is 5.83% of the total shares[11] - The company reported a total of 56,644,160 shares under lock-up agreements, with 18,379,640 shares released during the period[14] Research and Development - The company plans to maintain its focus on research and development of new products and technologies to enhance market competitiveness[12] - Research and development expenses for Q1 2023 were CNY 13,945,439.84, slightly up from CNY 13,701,030.39 in the previous year[19] Other Information - The company received government subsidies amounting to ¥1,835,702.90 during the reporting period[6] - The company did not conduct an audit for the first quarter report[24] - The company is exploring opportunities for market expansion and potential mergers and acquisitions to drive growth[12] - The company reported a decrease in financial asset impairment losses to -CNY 176,430.03 from -CNY 323,417.79 in the previous year[20]

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2023003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 4 月 13 日 (周四) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、泰林生物 董事长、总经理叶大林 | | 员姓名 | 2、泰林生物 董事会秘书兼财务总监叶星月 | | | 3、独立董事杨忠智 | | | 4、保荐代表人严绍东 | | | 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、公司最有核心竞争力的产品是什么 | | | 答：尊敬的投资者，您好！公司 ...

Financial Performance - The company's operating revenue for 2022 was CNY 373,878,114.24, representing a 32.00% increase compared to CNY 283,248,491.21 in 2021[19]. - The net profit attributable to shareholders for 2022 was CNY 79,686,202.54, a 25.43% increase from CNY 63,529,851.10 in 2021[19]. - The cash flow from operating activities for 2022 was CNY 89,385,619.71, showing a significant increase of 148.56% from CNY 35,961,769.59 in 2021[19]. - The total assets at the end of 2022 amounted to CNY 922,660,005.83, a 40.68% increase from CNY 655,871,410.07 at the end of 2021[19]. - The company reported a basic earnings per share of CNY 0.96 for 2022, up 26.32% from CNY 0.76 in 2021[19]. - The company achieved operating revenue of ¥373,878,114.24, a year-on-year increase of 32.00%, and a net profit attributable to shareholders of ¥79,686,202.54, up 25.43% compared to the previous year[59]. - Total assets reached ¥922,660,005.83, reflecting a growth of 40.68% year-on-year[59]. - Revenue from the pharmaceutical industry amounted to ¥344,999,759.36, accounting for 92.28% of total revenue, with a year-on-year growth of 36.02%[79]. - The gross profit margin for the pharmaceutical industry was 50.34%, a decrease of 8.46% compared to the previous year[82]. Research and Development - The company is actively engaged in research and development of new technologies, including vaporized hydrogen peroxide sterilization systems[12]. - The company is actively engaged in the research and development of life science instruments and new biopharmaceutical equipment, with a focus on cell therapy-related equipment[31]. - The company has established a multi-level R&D system, including the TaiLin Research Institute and various specialized research centers, to enhance its continuous R&D capabilities[45]. - The company invests over 10% of its sales revenue annually into technology research and new product development, resulting in a total of 334 technology patents, including 28 invention patents[50]. - The company has 55 ongoing research and development projects, indicating a strong focus on innovation and technology advancement[108]. - The company has launched products targeting the cell therapy industry and biodegradation testing, but faces challenges in market acceptance and competition[132]. Product Development and Market Strategy - The company aims to expand its market presence through strategic partnerships and acquisitions in the biotechnology sector[12]. - The company is focusing on expanding its product line to include a variety of specifications for different customer needs in the biological product and cell culture industries[92]. - The company is focusing on product development in precision medicine and medical devices to create new business growth points[126]. - The company plans to enhance its international competitiveness by improving product design and user experience through collaboration with professional design teams[94]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[197]. - New product lines are anticipated to launch in Q3 2023, expected to contribute an additional 200 million RMB in revenue[198]. Corporate Governance and Management - The company maintains a strong commitment to corporate governance and transparency in its operations[145]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[139]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[141]. - The company has implemented a robust internal audit system to ensure the authenticity and completeness of financial information[140]. - The company has established a risk management organization comprising the audit committee and internal audit department to oversee internal controls[181]. - The company has a transparent and open process for appointing senior management personnel[141]. Environmental and Social Responsibility - The company has committed to strict compliance with environmental regulations, continuously improving processes to reduce energy consumption and pollutant emissions[191]. - The company has developed a comprehensive environmental management system to monitor and control significant environmental impacts[188]. - The company has a focus on protecting employee rights, providing a safe working environment, and ensuring compliance with labor laws[190]. - The company has established a monitoring program to ensure compliance with environmental performance targets and legal standards[188]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[187]. Future Outlook and Strategic Initiatives - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[199]. - A strategic acquisition of a smaller biotech firm is expected to be finalized by Q2 2023, which will enhance the company's product portfolio[199]. - The company plans to implement its first stock incentive plan post-IPO and enhance performance assessment for core employees to boost motivation[126]. - The company is implementing cost-cutting measures aimed at reducing operational expenses by 15% over the next year[199]. - The company plans to repurchase shares using its own funds, with a total amount not exceeding the funds raised from its latest public offering of A-shares[200].

浙江泰林生物技术股份有限公司（以下简称"公司"）定于2023年4月13日（周 四）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采 用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理叶大林先生、董事会秘书兼 财务总监叶星月先生、独立董事杨忠智先生、保荐代表人严绍东先生。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 12日（星期三）17:00前访问https://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在2022年度业绩说明会上，对投资者普遍关注的问 题进行回答。 欢迎广大投资者积极参与本次网上说明会。 | 证券代码：300813 | 证券简称：泰林生物 | 公告编号：2023-030 | | --- | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | | 浙江泰林生物技术股份有限公司 关 ...

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. was listed on the Shenzhen Stock Exchange in January 2020 as a high-tech enterprise focused on life science system solutions [1] - The company specializes in biotechnology, precision medicine, pharmaceutical engineering, food safety, and new materials, providing a comprehensive range of equipment, precision instruments, and consumables [1] Client Base and Market Reach - The company serves thousands of clients across various sectors, including pharmaceutical companies, food and drug inspection agencies, healthcare institutions, and research units [2] Production Capacity - As of now, the company operates three production bases located in Binjiang headquarters, Fuyang No. 7 Road Park, and Fuyang No. 2 Road Park [2] - The Binjiang headquarters focuses on the R&D and production of organic analysis products, while the Fuyang No. 7 Road Park specializes in microbiological testing technology [2] Research and Development - The company holds over 330 national patents and nearly 70 software copyrights, participating in the formulation of 27 national and industry standards [2] - Future R&D will focus on "domestic innovation, import substitution, and high-end positioning," emphasizing independent innovation [2] Cell Therapy Developments - In 2022, the company made progress in the field of cell and gene therapy, enhancing its product line and developing solutions for cell preparation and automated production equipment [2]

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2020002 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 上海交通大学教育集团国际金融研究院--林南均 | | 人员姓名 | | 上海交通大学教育集团国际金融研究院--方黎宏 | | | 宏信证券有限责任公司--孙瑱 | | | | 宏信证券有限责任公司—钱秋华 | | | | 长城证券股份有限公司--林毅 | | | | 北京股商投资有限公司--李涛 | | | | 恒泰证券股份有限公司--王宝 | | | | | 浙江浙商健投资产管理有限公司 ...

编号：2020001 证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者 | | | 人员姓名 | | | | 时间 | 2020 年 5 月 13 | 日上午 9:00-11:00 | | 地点 | 全 景 • 路 演 天 下 （ 121244.shtml ） | http://rs.p5w.net/html/ | | 上市公司接待人 | 董事长、总经理：叶大林先生 | | | 员姓名 | 董事、副总经理：沈志林先 ...